Teva Pharmaceutical Industries

What they make

5 inputs Teva Pharmaceutical Industries supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Substitution2023

  Teva was one of the largest defendants in the U.S. opioid litigation, accused of helping fuel the addiction crisis through its generic and branded opioid products. The way it settled is a striking dual role: as part of a roughly $4.25 billion national settlement, Teva agreed to provide a very large supply of generic naloxone — the nasal-spray drug that reverses opioid overdoses — valued in the billions. So the same company that manufactured opioids became, by court settlement, a major supplier of the antidote that saves people from overdosing on them. It is an unusually literal example of one firm sitting on both sides of a public-health crisis — making both the substance implicated in the harm and the medicine that undoes it — and of how legal settlements can quietly reshape who supplies a life-saving drug. [verify: HDPE dominant for drip tape; no-credible-substitute reasonable, not contradicted]

  Teva Pharmaceutical Industries Ltd. (TEVA) ↗

• Did you know2024

  The world's single largest maker of generic medicines is an Israeli company, and its products are so ubiquitous that an enormous share of prescriptions filled in the United States and Europe are Teva pills under store or generic labels. Beyond finished drugs, Teva runs TAPI, one of the largest merchant manufacturers of active pharmaceutical ingredients — meaning Teva also sells the raw drug substances to its own competitors. So a single firm from Petah Tikva sits at two layers of the global medicine supply at once: the finished generic in the bottle, and the API that rival generics makers depend on to make their own versions. The world's medicine cabinet runs, to a degree almost nobody appreciates, through one Israeli company — both as the brand on the label and as the chemistry behind competitors' labels.

  Teva Pharmaceutical Industries Ltd. (TEVA) ↗

• Origin2024

  Teva's roots go back to 1901, when it began as a small drug-wholesaling business in Jerusalem, distributing medicines by camel and donkey across Ottoman- and then British-Mandate Palestine. Over the 20th century it consolidated Israel's fragmented pharmaceutical sector and became the country's defining industrial multinational — its very name, Teva, is Hebrew for "nature." Its leap to global scale was funded in large part by Copaxone, a multiple-sclerosis drug developed from research at Israel's Weizmann Institute that became a multibillion-dollar branded blockbuster; the cash from that homegrown innovation bankrolled Teva's acquisition spree into the world's largest generics empire. It is a rare case of a national science institution's discovery financing a country's rise to dominance in a global commodity-drug market.

  Teva Pharmaceutical Industries Ltd. (TEVA) ↗